CONSENSUS STATEMENT

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)

D E Furst¹, F C Breedveld², J R Kalden³, J S Smolen⁴, C E Antoni⁵, J W J Bijlsma⁶, G R Burmester⁷, B Cronstein⁸, E C Keystone⁹, A Kavanaugh¹⁰ and L Klareskog¹¹

¹ University of California, Los Angeles, CA, USA
² Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
³ Medizinische Klinik III, Friedrich Alexander Universität, Erlangen, Germany
⁴ Abteilung für Rhumatologie, Universitätsklinik für Innere Medizin III, Wien, Austria
⁵ Medizinische Klinik III, Friedrich Alexander Universität, Erlangen, Germany
⁶ Department of Rheumatology, University Medical Centre Utrecht, Utrecht, The Netherlands
⁷ Department of Rheumatology and Clinical Immunology, Charité Hospital, Berlin, Germany
⁸ New York University School of Medicine, New York, NY, USA
⁹ Department of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada
¹⁰ Division of Rheumatology, University of California, San Diego, La Jolla, CA, USA
¹¹ Rheumatology Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden

Correspondence to:
Correspondence to:
Dr D E Furst, 1000 Veteran Avenue Rehabilitation Center, Room 32–5, Los Angeles, CA 90024, USA;
defurst@mednet.ucla.edu

Keywords: tumour necrosis factor ; blocking agents; rheumatoid arthritis; biological agents

Abbreviations: aCL, anticardiolipin antibody; ACR, American College of Rheumatology; ANA, antinuclear antibody; DAS, disease activity score; DMARD, disease modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire disease index; IL, interleukin; MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumour necrosis factor; VAS, visual analogue scale

The first 150 words of the full text of this article appear below.

A s in previous years, the consensus group to consider the use of biological agents was formed by an organising committee constituted of rheumatologists from the Universities of Erlangen, Leiden, and Vienna in Europe in cooperation with universities in the United States, Canada, and Europe. Pharmaceutical industry support was obtained from a number of companies, but these institutions had no part in the decisions about the specific programme or about the academic participants at this conference.

The 158 rheumatologists and bioscientists from 22 countries who attended the consensus conference were chosen from a worldwide group of people felt to have experience or interest in the use of biological agents for the treatment of rheumatoid arthritis (RA) and other rheumatic diseases. Unfortunately, the number of attendees and participants was limited so that not everyone who might have been appropriate could be invited.

Additional information has come to light in the past . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• KOIKE, T., HARIGAI, M., INOKUMA, S., INOUE, K., ISHIGURO, N., RYU, J., TAKEUCHI, T., TANAKA, Y., YAMANAKA, H., FUJII, K., FREUNDLICH, B., SUZUKAWA, M. (2009). Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. The Journal of Rheumatology 36: 898-906 [Abstract] [Full Text]  
• van der Heijde, D, Landewe, R, van Vollenhoven, R, Fatenejad, S, Klareskog, L (2008). Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 67: 1267-1270 [Abstract] [Full Text]  
• van Riel, P L C M, Freundlich, B, MacPeek, D, Pedersen, R, Foehl, J R, Singh, A, on behalf of ADORE study investigators, (2008). Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 67: 1104-1110 [Abstract] [Full Text]  
• Bombardieri, S., Ruiz, A. A., Fardellone, P., Geusens, P., McKenna, F., Unnebrink, K., Oezer, U., Kary, S., Kupper, H., Burmester, G. R., on behalf of the Research in Active Rheumatoid Art, (2007). Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46: 1191-1199 [Abstract] [Full Text]  
• Leeb, B. F., Andel, I., Sautner, J., Nothnagl, T., Rintelen, B. (2004). The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford) 43: 1504-1507 [Abstract] [Full Text]  
• Breedveld, F C, Kalden, J R (2004). Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 63: 627-633 [Abstract] [Full Text]  
• Sidiropoulos, P, Bertsias, G, Kritikos, H D, Kouroumali, H, Voudouris, K, Boumpas, D T (2004). Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 63: 144-148 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Dougados, M, Emery, P, Gibofsky, A, Kavenaugh, A F, Keystone, E C, Klareskog, L, Russell, A S, van de Putte, L B A, Weisman, M H (2003). Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 62: ii2-9 [Full Text]  
• Hochberg, M C, Tracy, J K, Hawkins-Holt, M, Flores, R H (2003). Comparison of the efficacy of the tumour necrosis factor {alpha} blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 62: ii13-16 [Abstract] [Full Text]  
• Flendrie, M, Creemers, M C W, Welsing, P M J, den Broeder, A A, van Riel, P L C M (2003). Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 62: ii30-33 [Abstract] [Full Text]  
• Braun, J, Sieper, J, van der Heijde, D (2003). Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. Ann Rheum Dis 62: 1023-1024 [Full Text]  
• Braun, J, Pham, T, Sieper, J, Davis, J, van der Linden, S., Dougados, M, van der Heijde, D (2003). International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62: 817-824 [Abstract] [Full Text]